Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved crizotinib for reimbursement as a treatment option for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer, and whose ALK rearrangement has been demonstrated by an accurate and validate test method.

This is written in the approval document as:

Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Reimbursement

CDS

Citation

Crizotinib Monotherapy, 2025, version number 7, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6934/243_V7_Crizotinib_Monotherapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2014-06-01	Health Service Executive	Indication approved for reimbursement.